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Purpose. To compare gene expression profiles and drug permeability
differences in Caco-2 cell culture and human duodenum.
Methods. Gene expression profiles in Caco-2 cells and human duo-
denum were determined by GeneChip® analysis. In vivo drug per-
meability measurements were obtained through single-pass intestinal
perfusion in human subjects, and correlated with in vitro Caco-2
transport permeability.
Results. GeneChip® analysis determined that 37, 47, and 44 percent
of the 12,559 gene sequences were expressed in 4-day and16-day
Caco-2 cells and human duodenum, respectively. Comparing human
duodenum with Caco-2 cells, more than 1000 sequences were deter-
mined to have at least a 5-fold difference in expression. There were
26, 38, and 44 percent of the 443 transporters, channels, and metabo-
lizing enzymes detected in 4-day, 16-day Caco-2 cells, and human
duodenum, respectively. More than 70 transporters and metabolizing
enzymes exhibited at least a 3-fold difference. The overall coefficient
of variability of the 10 human duodenal samples for all expressed
sequences was 31% (range 3% to 294%) while that of the expressed
transporters and metabolizing enzymes was 33% (range 3% to 87%).
The in vivo / in vitro drug permeability measurements correlated well
for passively absorbed drugs (R2  85%). The permeability correla-
tion for carrier-mediated drugs showed 3- 35-fold higher in human
above the correlation of passively absorbed drugs. The 2- 595-fold
differences in gene expression levels between the Caco-2 cells and
human duodenum correlated with the observed 3- 35-fold difference
in permeability correlation between carrier-mediated drugs and pas-
sively absorbed drugs.
Conclusions. Significant differences in gene expression levels in
Caco-2 cells and human duodenum were observed. The observed
differences of gene expression levels were consistent with observed
differences in carrier mediated drug permeabilities. Gene expression
profiling is a valuable new tool for investigating in vitro and in vivo
permeability correlation.
KEY WORDS: gene expression; transporter; GeneChip®; perme-
ability; in vivo/in vitro correlation.
INTRODUCTION
Caco-2 cells, which are polarized epithelial cells, can
form a differentiated monolayer that resembles the human
intestinal epithelium. Numerous efforts have been made to
use in vitro Caco-2 cells’ permeability data to predict the
fraction of drug absorbed in humans (1). However, the gene
expression profiles of the Caco-2 cells and human intestine
might be different. One report appeared in which correlation
of the mRNA levels of 10 drug efflux transporters was per-
formed between Caco-2 cells and human jejunum by RT-PCR
(2). However, a comprehensive comparison of gene expres-
sion and an extensive in vivo/in vitro permeability correlation
between Caco-2 cells and human intestine has not been re-
ported.
While attempts to predict fraction drug absorbed in vivo
using in vitro Caco-2 permeability data have had some success
for passively absorbed drugs, the results for carrier-mediated
drugs have been less successful (3–5). Lipophilic drugs, which
are mainly absorbed through passive membrane diffusion,
have shown good correlation between in vitro Caco-2 cells
and in vivo intestinal permeability. However, hydrophilic
drugs, which are absorbed by paracellular or carrier-mediated
transport processes show a significantly different in vivo/in
vitro permeability correlation. It has been suggested that
many clinically used drugs including cephalexin, amoxicillin,
lisinopril, enalapril, cimetidine, L-dopa, and glucose are ab-
sorbed, at least in part, through transporter-mediated absorp-
tion process (6–10).
In this study, the expression profiles of 12,559 gene se-
quences including 443 transporters, channels, and metaboliz-
ing enzymes were measured using GeneChip® analysis to de-
termine the differences mRNA expression between Caco-2
cells and human duodenum. In addition, the in vivo intestinal
permeabilities of 26 drugs determined in healthy human sub-
jects are correlated with the in vitro Caco-2 cell permeability
determined in this laboratory and from the literature
(1,3,4,11–25). This report summarizes the differences that
were observed in the mRNA expression profiles and in the
observed permeabilities.
The expression results, far too extensive to present in this
report, are also available online for the all transporters and




TRIzol reagent and SuperScript Choice System for
cDNA synthesis kit were purchased from Gibco BRL (Grand
Island, NY, USA). BioArray high yield RNA transcript la-
beling kit was purchased from Enzo Biochem (New York,
NY, USA). Genechips were purchased from Affymetrix
(Santa Clara, CA, USA). The genechip hybridization and
scanning was performed at the Genomic Information Support
Facility at the Michigan State University (E. Lansing, MI,
USA). Healthy male or female volunteers between 21 and 45
years of age and within 20% of their ideal body weight were
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enrolled in the study. The clinical study protocols were ap-
proved by the IRB of the University of Michigan. A Loc-I-
gut® perfusion tube was purchased from Pharmacia (Pea-
pack, NJ, USA). Tissue culture plates were purchased from
Becton Dickinson Labware (Bedford, MA, USA). All cell
culture medium and reagents were from Gibco BRL (Grand
Island, NY, USA).
GeneChip® Analysis
Human duodenum tissues or Caco-2 cells (passage 32–
40) were homogenized in TRIzol reagent (Gibco) and the
RNA phase was separated by chloroform, total RNA was
precipitated with isopropyl alcohol, and washed with 80%
ethanol. Total RNA was further cleaned with RNeasy mini
kit (Qiagen). First-strand cDNA was transcribed from total
RNA using T7-(dT)24 oligomer primer and SSII reverse tran-
scriptase at 42°C. The second strand cDNA synthesized from
first-strand cDNA using DNA ligase, DNA polymerase I and
T4 DNA polymerase at 16°C (SuperScript Choice System for
cDNA synthesis kit, Gibco), then cleaned with Phase-Locking
gel. Biotin-labeled cRNA synthesized from the double strand
cDNA using T7 RNA polymerase-catalyzed in vitro transcrip-
tion in the presence of biotin-labeled NTP (BioArray high
yield RNA transcription labeling kit, Enzo Biochem) then
fragmented at 95°C. Biotin-labeled cRNA was heated at
99°C for 5 min in hybridization cocktail including hybridi-
zation control (Bio B, C, D, and Cre) and hybridized with
GeneChip® (Affymetrix) at 42°C for 16 h. The GeneChip®
was then washed with non-stringent wash buffer at 50°C and
stained with streptavidin phycoerythrin (SAPE) solution. Af-
ter washing at 25°C, the GeneChip® was scanned with a laser
scanner (Affymetrix). The gene expression profiles were ana-
lyzed by Affymetrix Microarray Suite and Data Mining Tool
software.
Western Blot Analysis and RT-PCR
For Western blot analysis, Caco-2 cells were washed
twice with phosphate-buffered saline (PBS) and collected in
0.5 ml PBS with 1 mM PMSF (phenylmethysulfonyl fluoride)
and 60 g/ml of soybean trypsin inhibitor, and sonicated three
times for 20 s. Human duodenum tissue was homogenized in
PBS with 1 mM PMSF and 60 g/ml of soybean trypsin in-
hibitor. The cell suspension or tissue homogenate were incu-
bated with 2× SDS loading buffer for 30 m at room tempera-
Fig. 1. Scatter analysis of the expression of 12,000 genes in human duodenum and Caco-2 cells. The X and Y axis represent the expression
levels of genes by its hybridization signal density in human duodenum or Caco-2 cells. Red color indicates the genes are present in both
samples. Blue color indicates the genes are present in one sample, but absent in the other. Yellow color indicates the genes are absent in both
samples. Green lines on both sides of the dots indicate the genes with expression levels 2-fold, 3-fold, 5-fold, or 10-fold more in one sample
than in the other, respectively.
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ture and then 15 g of protein was subjected to electropho-
resis in 4–20% SDS-polyacrylamide gels (Bio-Rad). The
protein was transferred to Hybond-P PVDF transfer mem-
brane for 1.5 h under 250 mA. The membrane was incubated
with an anti-hPepT1 polyclonal antibody (1:1000 in 2.5% milk
Tris-buffered saline with 0.1% tween-20 (TBS-T), provided
by Dr. Wolfgang Sadee at UCSF) at room temperature for 1
h, washed 4 times with TBS-T for 15 min then incubated with
horseradish peroxidase conjugated secondary antibody (Jack-
son ImmunoResearch Labs, West Grove, PA, USA) for 1 h at
room temperature. An enhanced chemiluminescence system
ECL+Plus (Amersham) was used to detect hPepT1 expres-
sion level.
For RT-PCR, total RNA from the tissue and Caco-2 cell
samples was purified using Trizol reagent (Gibco). One mi-
crogram of total RNA from each sample was subjected to
RT-PCR (PCR Access system, Promega) using hPepT1 spe-
cific primers. The primers corresponded to nucleotide posi-
tions 342–360 (forward primer) and 1575–1592 (reverse
primer) of the cDNA. The first strand cDNA was synthesized
using AMV reverse transcriptase (AMV RT) at 48°C for 45
min. This was followed by a 2 min cycle at 94°C to inactivate
AMV RT and to denature the primers and cDNA. The PCR
was performed for 25 cycles of 94°C for 30 s, primer annealing
for 1 min at 54°C, extension at 68°C for 2 min, and a final
extension at 68°C for 7 min. The conditions were established
to obtain linear amplification of PCR product. The expected
hPepT1 PCR fragment was 1.2 kb. The reaction mixture was
separated on a 4%–20% TBE -polyacrylamide gel (Novex)
and visualized with SYBR Green nucleic acid gel stain (Mo-
lecular Probes).






Caco-2 4 days 4635 ± 2926 12,559
Caco-2 16 days 5908 ± 871 12,559
Human duodenum 5882 ± 1035 12,559
Fig. 2. Scatter analysis of the expression of 12,000 genes in human duodenum and Caco-2 cells. The X- and Y-axis represent the expression
levels of genes by its hybridization signal density in human duodenum or Caco-2 cells. Red color indicates the genes are present in both
samples. Blue color indicates the genes are present in one sample, but absent in the other. Yellow color indicates the genes are absent in both
samples. Green lines on both sides of the dots indicate the genes with expression levels 2-fold, 3-fold, 5-fold, or 10-fold more in one sample
than in the other, respectively.
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Clinical Human Intestinal in Situ Perfusion Study
Human subjects were fasted for approximately 7 h, and
then underwent esophagogastroduodenoscopy (EGD). Ten
biopsy samples were taken from the duodenum with endo-
scope guidance. Subsequently, a 6-lumen perfusion tube
(Loc-I-Gut®), which contained 2 inflatable balloons, was in-
troduced orally into the upper jejunum with the guidance of
EGD. Twenty to thirty milliliters of air was used to inflate
each balloon to create a 10 cm closed intestinal segment. The
segment was then perfused with a solution containing 10 M
test drug, 1 mg/l dl-propranolol, 10 mg/l l-phenylalanine, 5 g/l
PEG 4000, 5 g/l PEG 400, 5.4 mM KCl, 45 mM NaCl, 21 mM
Na2HPO4, 49 mM NaH2PO4.H2O, 35.1 mM D-mannitol and
10 mM D-glucose at a flow rate of 3 ml/min for 120 min. The
pH and osmolarity of the perfusate solution were adjusted
to 6.5 and 300 mOsm/l, respectively. PEG 4000, a non-
absorbed compound, was used to correct for water secretion
or absorption in the perfused segment. Total of 26 drugs
were tested, which included cephalexin, hydrochlorothiazide,
furosemide, atenolol, cimetidine, amoxicillin, lisinopril,
losartan, metoprolol, propranolol, desipramine, naproxen,
ketoprofen, D-glucose, proxicam, ranitidine, verapamil,
cyclosporin, enalapril, phenylalanine, antipyrine, terbutaline,
L-dopa, L-leucine, creatine, and manitol (26–35). The per-
meability was calculated using the following equation:
Peff = Q (1-Cout/Cin) / 2RL. Where Peff is effective perme-
ability, Q is perfusion rate (ml/min), Cout and Cin are the
outlet and inlet drug concentrations, R is the radius of human
jejunum (1.75 cm), and L is the length of perfusion seg-
ment (10 cm).
Table II. The Number of Genes Expressed with More than 5-Fold Difference in Comparison of Human Duodenum and Caco-2 Cells
Number of genes with
more than 5-fold
expression difference
Number of genes with
more than 5-fold
expression increase
Number of genes with
more than 5-fold
expression decrease
Caco-2 16 days vs. Caco-2 4 days 239 ± 106 155 ± 0.7 83 ± 103
Human duodenum vs. Caco-2 4 days 1112 ± 449 614 ± 176 460 ± 330
Human duodenum vs. Caco-2 16 days 925 ± 147 516 ± 119 408 ± 39
Table III. The Number of the Transporters, Channels and Metabolizing Enzymes Expressed in Caco-2









peptide transporters 2 2 3 4
Na+/H+ exchangers 2 3 3 7
Na+/K+ ATPase 2 4 3 7
Amino acid transporters 7 8 8 25
Nucleoside transporters 2 3 3 5
Organic cation transporters 1 2 2 7
Organic anion transporters 4 5 11 17
Glucose transporters 5 7 6 11
Ion exchangers 1 2 1 6
Phosphate transporters 2 3 2 6
P-gp 2 2 2 5
MRP 4 3 4 7
Other ABC transporters 0 0 0 3
Fatty acid transporters 1 1 2 3
Bile acid and bile salt transporters 1 0 0 3
Amine transporters 1 1 1 7
Citrate transporters 2 2 2 2
Mitochondria solute carrier 2 4 3 6
Ubiquitin carriers 3 3 3 3
Other transporters 7 12 11 19
Proton pumps and H+ ATPase 7 8 9 10
Other ion ATPase 6 7 7 15
Ion transporters 1 1 1 5
Channels 8 17 20 111
Junction proteins 3 3 4 7
Villin 1 3 3 4
Mucin 2 3 6 19
Alkaline phosphatase 0 0 2 3
Esterase and other related 7 9 8 15
Cytochrome P-450 6 11 25 44
Phase II metabolism enzymes 25 37 39 57
Total 117 166 194 443
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Uptake Permeability of Cephalexin in Caco-2 Cells
Caco-2 cells were grown at 37°C, 5% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal
bovine serum, 1% nonessential amino acids, 1 mM sodium
pyruvate, 1% L-glutamine. Caco-2 cells were seeded into
6-well culture plates at the density of 104 cells/cm2. Three
days after seeding, cells were washed twice with 2 ml of
pH 6.5 uptake buffer containing 1 mM CaCl2, 1 mM MgCl2,
150 mM NaCl, 3 mM KCl, 1 mM NaH2PO4, 5 mM D-
glucose and 5 mM MES. Then 1 ml uptake buffer with 0.1
mM cephalexin was added in each well and agitated on a
plate shaker at 37°C. At different time point (10–120 min),
cells were washed 3 times with ice-cold pH 6.5 uptake buf-
fer, and 1 ml water was added into each well. Cells were
collected in an eppendorf tube, sonicated for 5 min and pro-
tein was precipitated with 4% trifluoroacetic acid (TFA).
After centrifugation at 3000 rpm for 5 min, the supernatant
was filtered using a membrane filter (0.45 m). The cepha-
lexin concentration was measured by reverse-phase HPLC
assay (SUPELCOSIL LC-8-DB column, 5C18, 4.6 × 250 mm,
SUPELCO) at 250 nm. Protein concentrations before add-
ing TFA were determined using Bio-Rad protein dye re-
agent (Bio-Rad, Hercules, CA). The cephalexin uptake per-
meability was calculated by the following equation: Peff =
(dQ/dt) / A C0 Pt. Where dQ/dt is the uptake rate (mmol/
min), A is surface area of the well, C0 is initial drug concen-
tration in each well, and Pt is the amount of cell protein in
each well.
RESULTS
Summary of Expression for 12,559 Sequences in Caco-2
Cells and Human Duodenum
The scatter plots for the 12,559 sequences are showed in
Fig. 1 and Fig. 2. Significantly greater scatter is observed when
comparing the expression profiles for human duodenum vs.
Caco-2 cells than when comparing human-human or Caco2-
Caco2 expression.
For the 12,559 sequences analyzed, there were 4635 ±
2926, 5908 ± 871, and 5882 ± 1035 genes determined to have
significant expression in Caco-2 cells (4 days), Caco-2 cells (16
days), and human duodenum respectively. While similar num-
bers of sequences were detected in Caco-2 cells and human
duodenum, more than 1000 (17%) of the gene sequences
were determined to have at least a 5-fold difference when
comparing human duodenum with Caco-2 cells (Table I, II).
Expression of Transporters, Channels, and
Metabolizing Enzymes
The expression of 443 transporters, channels, and me-
tabolizing enzymes was measured (Table III), of which, 117,
166, and 194 were detected in Caco-2 (4 days), Caco-2 (16
days), and human duodenum respectively. When comparing
human duodenum with Caco-2 cells, more than 70 transport-
ers, channels, and metabolizing enzymes were determined to
be at least 3-fold different in expression, while only 28 were
seen with at least a 3-fold difference when comparing Caco-2
cells (16 days) with Caco-2 cells (4 days).
The Variability of Gene Expression in Human Duodenum
Although some genes exhibited high expression variabil-
ity with a CV greater than 50% and difference (maximum/
Fig. 3. Box Whisker plot of the expression levels of transporters and
metabolizing enzymes with CV more than 50% in 10 human indi-
viduals. Shaded box indicated 25–75% of expression range, and error
bar indicated 10–90% of expression range. UGT, UDT-
glucoronosyltransferanse; CNT2, Na/purine transporter (CNT2);
GST, Glutathione S-transferase; CYP, Cytochrome P450; SBC, So-
dium/bicarbonate transporter. CoA-AT2, CoA acetyltransferase 2;
GLUT, Glucose transporter; GABA type 3, GABA transporter type
3; Carnitine T, Carnitine transporter; hCNT1, human nucleoside
transporter 1.
Fig. 4. Box Whisker plot of the expression levels of partial common
transporters and metabolizing enzymes with CV less than 50% in 10
human individuals. Shaded box indicated 25–75% of expression
range, and error bar indicated 10–90% of expression range. ALP,
Alkaline phosphatase; SGLT1 Na/glucose transporter (SGLT1);
CNT2, Na/purine transporter (CNT2); HPT1, human peptide trans-
porter 1 (Cadherin family); NADC1, Na/dicarboxylate cotransporter
1; y+LAT1, Amino acid transporter (y+LAT1); BPHL, Biphenyl hy-
drolase like protein; OCTN2, organic cation transporter (OCTN2);
GLUT5, Sodium-independent Glucose transporter 5; 4F2hc, Amino
acid transporter (4F2hc); MRP, multi-drug resistant associated pro-
tein; CYP, Cytochrome P450; hPepT1, human di-, tri-peptide trans-
porter 1; cMOAT (ABCC2), organic anion transporter (cMOAT);
MCT3, monocarboxylate transporter 3; MDR1, multidrug resistance
protein; ENT2, nucleoside transporter (ENT2).
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minimum) greater than 5 fold (Fig. 3), the majority of the 443
transporters, channels, and metabolizing enzymes showed
relatively low expression variability among the 10 duodenal
samples from normal human subjects. The average of CV (%)
for expression is 33 ± 20.22% (range 3.30% to 86.88%). The
overall coefficient of variability for all expressed sequences
was 31.02 ± 19.92% (range 3.30% to 294.27%). Several me-
tabolizing enzymes including CYP TCDD inducible, CYP
c11, CYP X02612, CYP 2A13, CYP 27, CYP 5, UGT U06641,
UGT 2B, and UGT 2B15 showed a larger variability with
more than 3.2–45-fold differences among 10 individuals. Sev-
eral transporters including GABA transporter type 3, glucose
transporter HepG2, Na/purine transporter (CNT2), carnitine
transporter, and Na/bicarbonate cotransporter2 (SBC2)
showed a high variability (CV more than 50%) with 3- to
14-fold difference (Fig. 3). Figure 4 shows the variability of
the common transporters and metabolizing enzymes with less
than 50% CV in 10 human duodenal samples. The gene ex-
pression variabilities in duodenum using GeneChip® analysis
are in agreement with the report for the variabilities of 10
drug efflux proteins in jejunum using RT-PCR (2).
In Vivo/in Vitro Drug Permeability Correlation
The in vivo intestinal permeability measurements of 26
drugs were obtained at the University of Michigan (Ann Ar-
bor, MI, USA) and the University of Uppsula (Sweden). The
in vivo permeability measurements were correlated with in
vitro Caco-2 cell transport permeabilities obtained from lit-
erature at both pH 6.5 and pH 7.4 (1,3,4,11–25) (Fig. 5, Fig. 6).
The correlation coefficient (r2) of permeability of all 24 drugs
determined at pH 7.4 was 0.5126 (log Peff,human  0.4926 × log
Peff, Caco-2 − 0.1454)., while the permeability correlation co-
efficient (r2) of the 20 drugs assayed at pH 6.5 was 0.7276 (log
Peff,human  0.6532 × log Peff, Caco-2 − 0.3036).
The in vivo/in vitro permeability correlation of the drugs
including cephalexin, enalapril, lisinopril, losartan, amoxicil-
lin, phenylalanine, L-leucine, L-dopa, D-glucose, cyclosporin,
and verapamil, which are transporter substrates deviated
from the trend of linear correlation at both pHs (Fig. 5, 6).
Removing the carrier-mediated absorbed drugs from the in
vivo/ in vitro permeability correlation improves the correla-
tion at both pHs. The correlation coefficient (r2) for the 15
Fig. 5. In vivo/in vitro permeability correlation of 20 drugs at pH 6.5. Human jejunum permeability was obtained through a single-pass
in situ intestinal perfusion study at the University of Michigan (USA) and Uppsala University (Sweden). In vitro Caco-2 cell permeability
was obtained from the literature (1–3,10–24). Correlation coefficient (r2  0.7276) was calculated from the permeability correlation of all
20 drugs. Correlation coefficient (r2  0.8492) was calculated from the permeability correlation of the following drugs: furosemide,
hydrochlorothiazide, atenolol, cimetidine, mannitol, terbutaline, metoprolol, propranolol, desipramine, antipyrine, piroxicam, ketoprofen,
and naproxen. Correlation coefficient (r2  0.7854) was calculated from the permeability correlation of the following drugs: cephalexin,
enalapril, lisinopril, losartan, amoxicillin, phenylalanine, L-leucine, L-dopa, D-glucose, cyclosporin, and verapamil. Drugs are labeled with
different symbols. Black symbols are carrier-mediated absorbed drugs, while gray and open symbols are passively absorbed drugs.
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passively absorbed drugs at pH 7.4 and 13 passively absorbed
drugs at pH 6.5 were 0.8376 (log Peff,human  0.6836 × log Peff,
Caco-2 − 0.5579) and 0.8492 (log Peff,human  0.7524 × log Peff,
Caco-2 – 0.5441) respectively. The in vivo/in vitro permeability
for only those carrier-mediated absorbed drugs also showed
reasonable correlation with a correlation coefficient (r2) of
0.6775 (log Peff,human  0.4898 × log Peff, Caco-2 + 0.3311) at
pH 7.4 and 0.7854 (log Peff,human  0.542 × log Peff, Caco-2 +
0.06) at pH 6.5, respectively. However, compared to the cor-
relation of passively absorbed drugs, the permeability of the
carrier-mediated absorbed drugs are with an average of 11-
fold (3- to 35-fold) higher in human than Caco-2 cells at pH
7.4, and with an average of 4-fold higher in human than
Caco-2 cells at pH 6.5.
Prediction of Fraction of Drug Absorbed with Human
Permeability and Caco-2 Permeability
Prediction of human drug fraction is shown in Fig. 7, 8, 9,
using human jejunal permeability (pH 6.5) and Caco-2 per-
meability at pH 6.5 and pH 7.4. A reasonable prediction can
be made from human jejunum permeability. However, the
prediction of fraction absorbed for the carrier-mediated drugs
with low Caco-2 permeability and high fraction absorbed is
poor.
DISCUSSION
The Expression of Di- and Tri-Peptide Transporters and
Comparison with Substrate Permeability
Four di- and tri-peptide transporters were determined
(Fig 10). The peptide transporter (hPepT1) expression was
very low in Caco-2 cells, but its expression in human duode-
num was 15-fold higher. Peptide transporter (HPT1), which is
related to the cadherin superfamily (36), was detected in high
levels in both Caco-2 cells and human duodenum. The
hPepT2 expression was undetectable in both Caco-2 cells and
human duodenum. The pH sensitive regulatory factor of pep-
tide transporter was also very low in both Caco-2 cells and
human duodenum tissue.
Even though drug permeability showed a better in vivo/
in vitro correlation at pH 6.5 than that at pH 7.4, the cepha-
lexin, amoxicillin, enalapril, and lisinopril permeability in hu-
Fig. 6. In vivo/in vitro permeability correlation of 24 drugs at pH 7.4. Human jejunum permeability was obtained through a single-pass in situ
intestinal perfusion study at the University of Michigan (USA) and Uppsala University (Sweden). In vitro Caco-2 cell permeability was
obtained from the literature (1–3,10–24). Correlation coefficient (r2  0.5126) was calculated from the permeability correlation of all 24 drugs.
Correlation coefficient (r2  0.8376) was calculated from the permeability correlation of the following drugs: furosemide, hydrochlorothiazide,
atenolol, ranitidine, cimetidine, mannitol, terbutaline, creatine, metoprolol, propranolol, desipramine, antipyrine, piroxicam, ketoprofen, and
naproxen. Correlation coefficient (r2  0.6775) was calculated from the permeability correlation of the following drugs: cephalexin, enalapril,
lisinopril, losartan, amoxicillin, phenylalanine, L-leucine, L-dopa, D-glucose, cyclosporin, and verapamil. Drugs are labeled with different
symbols. Black symbols are carrier-mediated absorbed drugs, while gray and open symbols are passively absorbed drugs.
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man deviated above the trend of linear correlation (Figs. 5
and 6). If their permeabilities were normalized by proprano-
lol permeability in both human jejunum and Caco-2 cells,
respectively, the human permeability ratios (drug permeabil-
ity/propranolol permeability) of cephalexin, amoxicillin,
enalapril, and lisinopril are always significantly higher (2.5- to
148-fold higher) than Caco-2 permeability ratios (Fig. 10). It
has been suggested that oral absorption of those drugs is me-
diated by hPepT1 transporter (6–8). The expression results
suggest that low hPepT1 expression is one of the main causes
for the low permeability in Caco-2 cells.
The expression levels of hPepT1 in Caco-2 cells and hu-
man duodenum were also determined by Western blot using
anti-hPepT1 antibody and RT-PCR analysis. There were un-
detectable levels of hPepT1 protein in Caco-2 cells (4 days
and 16 days), while human duodenum showed much higher
(8-fold) hPepT1 protein level than Caco-2 cells measured by
western blot analysis (Fig. 11A). However, the mRNA levels
of hPepT1 in Caco-2 cells were detected in Caco-2 cells (4
days and 16 days) through RT-PCR analysis, even though its
expression in Caco-2 cells was much lower (2.5-fold) than in
human duodenum (Fig. 11B). These hPepT1 expression pro-
Fig. 7. Prediction of drug fraction absorbed using human jejunum permeability. Drugs are labeled with different symbols. Closed symbols are
carrier-mediated absorbed drugs, while open symbols are passively absorbed drugs.
Fig. 8. Prediction of drug fraction absorbed using Caco-2 permeability at pH 6.5. Drugs are labeled with different symbols. Closed symbols
are carrier-mediated absorbed drugs, while open symbols are passively absorbed drugs.
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files obtained by Western blot and RT-PCR analysis were
similar to the results obtained by the GeneChip® assay. Fig-
ure 11C showed the comparison of the three different meth-
ods for the detection of hPepT1 expression. The GeneChip®
showed a 15-fold difference in hPepT1 expression in human
duodenum compared to Caco-2 cells (4 days), while RT-PCR
and Western blot analysis showed 2.5-fold and 8-fold differ-
ences respectively.
The Expression of Amino Acid Transporters and
Comparison with Substrate Permeability
GeneChip® analysis showed that seven out of twenty-
five amino acid transporters were detected in both Caco-2
cells and human duodenum (Fig. 12). Both glycoprotein as-
sociated amino acid transporter (y+LAT1) and membrane
glycoprotein 4F2 antigen heavy chain (4F2hc) were expressed
higher (2.5–4-fold) in Caco-2 cells than in human duodenum.
These two transporters were reported to form a heterodimer
for a functional complex to transport cationic and neutral
amino acids (10). Caco-2 cells expressed neutral amino acid
transporter B (ATB0) at more than12-fold higher levels than
that in human duodenum. Proline transporter (hPROT) ex-
pression was relatively abundant in both Caco-2 cells and
human duodenum. However, GABA/noradrenaline trans-
porter was detected at a more than 20-fold higher level in
human duodenum than Caco-2 cells.
L-dopa is thought to be absorbed by amino acid trans-
porters (10). Phenylalanine and leucine are also the substrates
for amino acid transporters. However, their permeability de-
viated above the linear trend in human intestine (Fig. 6).
Their human normalized permeability ratio (drug permeabil-
ity/propranolol permeability) is 1.5- to 273-fold higher than
normalized Caco-2 permeability ratio (Fig. 12), even though
the expression of all the amino acid transporters (on the
GeneChip®) were higher in Caco-2 cells compared to human
duodenum, with the exception of GABA transporter. It is
unlikely that L-dopa is absorbed by the GABA transporter
and other factors, such as the involvement of transporters not
on the chip or as yet unidentified may play a role in L-dopa
transport. Further, amino acid transporters usually have
broad substrate specificity, in which one amino acid might be
transported by several different amino acid transporters com-
plicating any correlation analysis.
Fig. 9. Prediction of drug fraction absorbed using Caco-2 permeability at pH 7.4. Drugs are labeled with different symbols. Closed symbols
are carrier-mediated absorbed drugs, while open symbols are passively absorbed drugs.
Fig. 10. (A). Expression of di- and tri-peptide transporters in Caco-2
cells (4 days, black bar), Caco-2 cells (16 days, gray bar), and human
duodenum (blank bar). Expression levels were quantified by the in-
tensity of hybridization signal. hPepT1, human proton/peptide trans-
porter 1; hPepT2, human proton/peptide transporter 2; hPepT1-RF,
pH-sensitive regulatory factor of peptide transporter; HPT1, peptide
transporter (LI-cadherin). (B). Normalized drug permeability ratio in
Caco-2 cells (pH 7.4, black bar), Caco-2 cells (pH 6.5, gray bar), and
human jejunum (blank bar). Normalized permeability ratio was cal-
culated by drug permeability/propranolol permeability in human and
Caco-2 cells, respectively. NA, data not available.
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The Expression of Organic Cation and Organic Anion
Transporters and Cimetidine Permeability
Only two organic cation transporters (OCTN1 and
OCTN2) out of seven organic cation transporters were de-
tected in human duodenum and Caco-2 cells (Fig. 13). Both
were expressed at higher levels in the human duodenum than
in Caco-2 cells. Human duodenum tissue had 2.8-fold higher
OCTN1 expression and 3-fold higher OCTN2 expression than
in Caco-2 cells (Fig. 13).
Nine out of seventeen organic anion transporters were
detected in human duodenum and Caco-2 cells. Three mono-
carboxylate transporters (MCT U59185, MCT U59299, and
MCT3) and two multispecific organic anion transporters
(ABC transporter: MOAT-C (ABCC5) and cMOAT
(ABCC2)) were expressed at similar levels in both human
duodenum and Caco-2 cells. However, human duodenum ex-
pressed very high levels of sodium/dicarboxylate transporter
(NADC1, 7-fold higher), sodium/bicarbonate cotransporters
(SBC) (78-fold higher SBC2, 7-fold higher pancrease SBC,
19-fold higher HNBC1) compared to Caco-2 cells (Fig. 13).
It has been reported that cimetidine might be a substrate
of the organic cation transporter (9). Yet, its permeability
showed reasonable in vivo/in vitro correlation even though
the human intestine expressed higher levels of organic cation
transporters (Fig. 5, 6). If cimetidine was only absorbed by
organic cation transporters, then we would expect that cimet-
idine would have higher permeability in the correlation curve
in human intestine than Caco-2 cells due to the differences in
expression levels of the organic transporters. These data sug-
gest that the absorption of cimetidine in vivo is not be exclu-
sively mediated by these two organic cation transporters
(OCNT1 and OCNT2).
Fig. 11. Expression of hPepT1 in Caco-2 cells and human duodenum by Western blot analysis and RT-PCR. (A). Western blot analysis of
hPepT1. hPepT1 (∼100 kDa) was detected only in human duodenum by rabbit anti-human hPepT1 antiboby . (B). RT-PCR amplify 1.2 kb
hPepT1 fragment from Caco-2 cells and human duodenum. (C). Comparison of Genechip, Western blot and RT-PCR analysis for hPepT1
expression. The fold change was calculated by the intensity of the band/intensity of the band in Caco-2 cells (4 days). The intensity of genechip
analysis was obtained by the fluorescence of hybridization signal, and intensity of the band in Western blot and RT-PCR was obtained using
Metaphor software.
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The Expression of Glucose Transporters and
Glucose Permeability
Five out of eleven glucose transporters were detected in
both Caco-2 cells and human duodenum (Fig. 14). There were
undetectable levels of the apical membrane localized sodium-
dependent glucose transporter (SGLT1) and apical mem-
brane localized sodium-independent glucose transporter
(GLUT5) in Caco-2 cells, while human duodenum expressed
more than 600-fold higher SGLT1 levels and 20-fold higher
GLUT5 than in Caco-2 cells. However, sodium-independent
glucose transporter (GLUT3), which is usually expressed in
neuron cells in human (37), was expressed more than 150-fold
higher in Caco-2 cells (4 days) than in human duodenum.
Similar levels of glucose transporter (HepG2) and UDP-
galactose transporter were detected in both human duode-
num and Caco-2 cells (Fig. 14). These results suggested that
Caco-2 cells are using a different mechanism for glucose up-
take than human duodenum.
Intestinal glucose absorption is mediated by glucose
transporters (SGLT1, GLUT5, and GLUT2). Its in vivo in-
testinal permeability is the highest among the 26 drugs we
tested, but its permeability in human was deviated above the
trend of linear correlation (Figs. 5 and 6). The human nor-
malized glucose permeability ratio (glucose permeability/
propranolol permeability) is 3- to 8-fold higher than Caco-2
permeability ratio (Fig. 14). This might be due to the fact that
human intestine expresses different types of glucose trans-
porters thereby using a different or multiple glucose uptake
pathways.
MDR, MRP Expression, and Cyclosporin
Verapamil Permeability
Five multidrug resistance genes (mdr) and seven multi-
drug resistance associated proteins (MRP) were measured by
GeneChip® analysis, six were detected in Caco-2 cells and
human duodenum (Fig. 15). Human duodenum and Caco-2
cells (4 days) expressed similar levels of multiple drug resis-
tance protein (p-glycoprotein, p-gp; mutidrug resistance gene,
mdr), however, human duodenum has 5-fold more p-gp ex-
pression than Caco-2 cells (16 days) (Fig. 15). The human
normalized permeabilities ratio (drug permeability/
propranolol permeability) of verapamil and cyclosporin,
Fig. 12. (A). Expression of amino acid transporters in Caco-2 cells (4 days, black bar), Caco-2 cells (16 days, gray bar), and human duodenum
(blank bar). Expression levels were quantified by the intensity of hybridization signal. y+LAT1, glycoprotein associated amino acid trans-
porter; ATB0, neutral amino acid transporter B; 4F2hc, membrane glycoprotein 4F2 antigen heavy chain; GABA, GABA/noradrenaline
transporter; hPROT, proline transporter Glutamate, glutamate transporter (accession number: U08989). (B). Normalized drug permeability
ratio in Caco-2 cells (pH 7.4, black bar), Caco-2 cells (pH 6.5, gray bar), and human jejunum (blank bar). Normalized permeability ratio was
calculated by drug permeability/propranolol permeability in human and Caco-2 cells, respectively. NA, data not available.
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which are substrates of p-gp, are 2- to 10-fold higher than
Caco-2 normalized permeability ratios (Fig. 15). The differ-
ence of p-gp expression between human intestine and Caco-2
cells (16 days) could not explain their in vivo/in vitro perme-
ability differences, which might suggest that there are other
unknown factors involved in their intestinal absorption. The
difference of mdr1 expression in 16 days Caco-2 cells and
human duodenum using GeneChip® analysis was not in
agreement with the report of mdr1 expression difference in 21
days Caco-2 cells and human jejunum using RT-PCR (2). This
might be due to the different culture conditions and the pas-
sage number of Caco-2 cells, the regional different of duode-
num and jejunum, as well as the different detection sensitivity
and amplification of mRNA by these two different methods.
RHOA proton-oncogene multidrug resistance protein
(RHOA) was expressed at similar level in both human duo-
denum and Caco-2 cells. All other multidrug resistance asso-
ciated proteins (MRP3B, MRP5, and MRP17) were ex-
pressed at similar levels in human duodenum and Caco-2
cells, with exception of MRP3, which was expressed 6-fold
more in human duodenum than in Caco-2 cells (4 days) (Fig.
15). The expression differences of MRP3 and MRP5 in
Caco-2 cells (16 days) and human duodenum detected by
GeneChip analysis were in agreement with the report of
their gene expression differences in Caco-2 cells (21 days) and
human jejunum detected by RT-PCR (2).
The Expression of Other Transporters and Ion Channels
All five nucleosides transporters, six phosphate trans-
porters, three fatty acid transporters, three bile acids trans-
porters, two citrate transporters, a creatinine transporter, a
sulfate transporter, a co-enzyme transporter, a ADP/ATP
transporter, a carnitine transporter, a glutarate transporter, a
sterol transporter, a serotonin transporter, and 111 ion chan-
nels were also analyzed. The expression profiles of some of
these transporters were at dramatically different levels in hu-
man duodenum compared to Caco-2 cells. Human duodenum
had 25-fold less nucleoside transporter (hENT1), 110-fold
higher sodium/purine transporter (CNT2), 360-fold more in-
testine fatty acid binding protein (FABP), 3-fold more liver
fatty acid binding protein, 6-fold more creatine transporter,
2–3-fold more sterol transporter, 4-fold more K+ channel
KLQT1, 26-fold more K+ channel TWK-1, and 350-fold more
calcium-dependent chloride channel-1 expression than in
Caco-2 cells.
Alkaline Phosphatase and Esterase Expression
All 13 carboxylesterases and 3 alkaline phosphatase were
measured for their expression, six of which were detected in
Caco-2 cells and human duodenum (Fig. 16). Human duode-
num expressed 100-fold greater alkaline phosphatase, 140-
Fig. 13. Expression of organic cation and organic anion transporters in Caco-2 cells (4 days, black bar), Caco-2 cells (16 days, gray bar), and
human duodenum (blank bar). Expression levels were quantified by the intensity of hybridization signal. OCTN1 and OCTN2, organic cation
transporter 1 and 2; MCT U59185, monocarboxylate transporter (accession number: U59185); MCT U59299, monocarboxylate transporter
(accession number: U59299); MCT3, monocarboxylate transporter 3; MOAT-C, ABC transporter MOAT-C; cMOAT, multispecific organic
anion transporter; NADC1, sodium/dicarboxylate cotransporter NADC1; SBC2, sodium/bicarbonate cotransporter 2; pancreas SBC, pancreas
sodium/bicarbonate cotransporter; HNBC1, sodium/bicarbonate cotransporter HNBC1.
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fold more putative carboxylesterase (Y09616), and 6-fold less
carboxylesterase (L07765) than Caco-2 cells. These results
suggest that phosphate prodrug and ester prodrug might have
different absorption and metabolism profiles in human intes-
tine and Caco-2 cells.
The Expression of Phase I and Phase II
Metabolizing Enzymes
The expression profiles of 44 cytochrome P-450 (CYP)
enzymes and 57 phase II metabolizing enzymes were ana-
lyzed. Only 20 CYPs and 32 phase II metabolizing enzymes
were detected in Caco-2 cells or human duodenum. Human
duodenum showed 49-fold more CYP h2B1, 17-fold more
CYP 2C9, 6-fold more CYP 2C18, 10-fold more CYP 2C19,
10-fold more CYP 2D, 20-fold more CYP 2J2, 160-fold more
CYP 3A4, 18-fold more CYP 4F2, 30-fold more CYP c11,
28-fold more CYP LTBV, 322-fold more CYP PCN3, and
37-fold more CYP (X65962) than Caco-2 cells (Fig. 17). The
difference in CYP 3A4 expression in Caco-2 cells and human
duodenum determined by GeneChip® analysis is in agree-
ment with the report of the difference of its expression in
Caco-2 cells and human jejunum by RT-PCR (2).
Phase II metabolism enzymes including UDP-
glucuronosyltransferase (UGT), glutathione S-transferase
(GST), sulfotransferase (ST), N-acetyltransferase (AT), and
acyltrtansferase (AcyT) in human duodenum and Caco-2 cells
were also dramatically different. Human duodenum had 17-
fold higher UGT2, 5-fold more UGT 2B15, 7-fold more UGT
(U06641), 8-fold more UGT C19, 7-fold more UGT (J05428),
117-fold more GST4, 10-fold more GST M4, 3-fold less GST
P1c, 4-fold more sulfotransferase 1A3, 4-fold more sulfotrans-
ferase P2, and 5-fold more N1-acetyltransferase (N1-AT)
than that of Caco-2 cells.
Fig. 14. (A). Expression of glucose transporters in Caco-2 cells (4 days, black bar), Caco-2 cells (16 days, gray bar), and human duodenum
(blank bar). Expression levels were quantified by the intensity of hybridization signal. HepG2, human (HepG2) glucose transporter; GLUT3,
sodium-independent glucose transporter-like protein III; GLUT5, sodium-independent glucose transporter-like protein 5; SGLT1, sodium-
dependent glucose cotransporter; UDP-galactose, UDP-galactose transporter related isoenzyme 1. (B). Normalized drug permeability ratio in
Caco-2 cells (pH 7.4, black bar), Caco-2 cells (pH 6.5, gray bar), and human jejunum (blank bar). Normalized permeability ratio was calculated
by drug permeability/propranolol permeability in human and Caco-2 cells, respectively. NA, data not available.
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SUMMARY
The enormous amount of data obtained with the
GeneChip® precludes a comprehensive analysis in this report.
Additional results are presented at the following link (http://
www.sitemaker.umich.edu/amidonlab/genechip_data). Over-
all, there were 37–44% of 12,559 gene sequences expressed in
Caco-2 cells and human duodenum with the chip comprising
about one third of the genes in the estimated human genome.
Comparing human duodenum with Caco-2 cells, more than
1000 genes were determined to have at least a 5-fold differ-
ence in expression. A 2- to 595-fold difference was observed
in expression of transporters, channels, and metabolizing en-
zymes between human duodenum and Caco-2 cells. The ex-
pression differences generally correlated with the 3- to 35-fold
higher permeability correlation in human for carrier-
mediated absorbed drugs than passively absorbed drugs
and with the limited expression data in the literature. The
GeneChip and the related technologies provide an invalu-
able new tool for investigating drug transport at a molecular
level and comparisons of transport in tissue culture and human.
APPENDIX
The list of Transporters and Metabolizing Enzymes
Exhibiting at Least 3-Fold Difference
Comparing human duodenum with Caco-2 cells (4 days),
the following are the transporters, channels, and metabolizing
enzymes with at least a 3-fold expression difference:
I. Gene expression with more than a 3-fold increase (3- to
595-fold): (a) Peptide transporters, amino acid transporter,
and related proteins: hPepT1, Na/K ATPase , GABA trans-
porter. (b) Organic cation and organic anion transporters:
MCT (U59185), MCT3, NADC1, SBC2, pancrease SBC, and
HNBC1. (c) Glucose transporters and nucleoside transport-
ers: SGLT1, GLUT5, and Na/purine transporter. (d) Other
transporters: Na/PO4 cotransporter, MRP3, intestinal fatty
acid binding protein (FABP), l iver FABP, UDP-
acetylglutosamine transporter, creatinine transporter, gluta-
rate transporter, and H+ pump 116 kDa. (e) Channels: K+
channel KLQT1, K+ channel TWK-1, Cl channel-1, Na chan-
Fig. 15. (A). Expression of MDRs and MRPs in Caco-2 cells (4 days, black bar), Caco-2 cells (16 days, gray bar), and human duodenum (blank
bar). Expression levels were quantified by the intensity of hybridization signal. MDR1, mutidrug resistance gene 1 (p-glycoprotein, p-gp);
RHOA MDR, RHOA proton-oncogene mutidrug resistance protein; MRP, multidrug resistance associated protein. (B). Normalized drug
permeability ratio in Caco-2 cells (pH 7.4, black bar), Caco-2 cells (pH 6.5, gray bar), and human jejunum (blank bar). Normalized perme-
ability ratio was calculated by drug permeability/propranolol permeability in human and Caco-2 cells, respectively. NA, data not available.
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nel, AQP-1, and water channel. (f) Alkaline phosphatase and
esterase: Alkaline phosphatase and putative carboxylesterase.
(g) Cytochrome P-450: 2A3, h2B1, 2C9, 2C18, 2C19, C11, 2D,
2J2, 3A4, 4F2, LTBV, PCN3, CYP reductase, CYP 27, TCDD
inducible CYP, and CYP (X65962). (h) Phase II metabolizing
enzymes: UDP-glucuronosyltransferase (UGT) including
UGT2, UGT 2B15, UGT (U06641), UGT C19, UGT
(J05428); acyltrtansferase (AcyT) including AcyT beta; glu-
tathione S-transferase (GST) including GST Ha2, GST4, GST
M4; sulfotransferase (ST) including ST 1A3, ST-P2, cerebro-
side ST, SULT 2B1b; and N-acetyltransferase (AT) including
N1-AT, AT PDC-E2. (i) Junction protein and microvilli re-
lated protein: Claudin-7, villin like protein, mucin 2, mucin 3,
mucin 6, pancrease mucin, and brush border myosin.
II. Gene expression with more than a 3-fold decrease (3-
to 172-fold): Amino acid transporter ATB0, glucose trans-
porter (GLUT3), cyclin-selected ubiquitin carrier, ubiquitin
carrier E2-EPF, Fe transporter, hydrogen carrier, carboxyles-
terase (L07765), palmitoyl thioesterase, CYP51, and 6-ST.
Comparing human duodenum with Caco-2 cells (16
days), the following are the transporters, channels, and me-
tabolizing enzymes with at least a 3-fold difference:
I. Gene expression with more than a 3-fold increase (3- to
595-fold): (a) Peptide transporters, amino acid transporters
and related proteins: hPepT1, NHE1, Na/K ATPase , and
GABA transporter. (b) Organic cation and organic anion
transporters: OCTN2, MCT3, MOAT-C, NADC1, SBC2,
pancrease SBC, and HNBC1. (c) Glucose transporters and
nucleoside transporters: SGLT1, GLUT5, and Na/purine
transporter. (d) Other transporters: Na/PO4 cotransporter,
mdr1, MRP5, intestinal FABP, liver FABP, creatinine trans-
porter, and H+ pump 116 kDa. (e) Channels: K channel
TWK-1, K channel KLQT1, K channel MaxiK, Cl channel-1,
Na channel, and AQP-1. (f) Alkaline phosphatase and ester-
ase: Alkaline phosphatase, neuropathy protein esterase, and
putative carboxylesterase. (g) Cytochrome P-450: h2B1,
2C9, 2C18, 2C19, C11, 2D, 2J2, 3A4, 4F2, LTBV, AKA,
PCN3, P-(1)-450 (X02612), CYP TCDD inducible, and
CYP (X65962). (h) Phase II metabolizing enzymes: UGT2,
UGT 2B15, UGT (U06641), UGT C19, UGT (J05428),
GST4, GST M4, ST 1A3, ST-P2, and N1-AT. (i) Junction
protein and microvilli related protein: Cardiac gap junction
protein, claudin-7, mucin 2, mucin 3, mucin 6, and brush bor-
der myosin.
II. Gene expression with more than a 3-fold decrease (3-
to 79-fold): Amino acid transporter (y+LAT1), amino acid
transporter ATB0, glutamate transporter (D26443), glucose
transporter (GLUT3), mitochondrial solute carrier, cyclin-
selected ubiquitin carrier, ubiquitin carrier E2-EPF, Fe trans-
porter, sulfate transporter, hydrogen carrier, carboxylesterase
(L07765), palmitoyl protein thioesterase, Ca++ channel 1, Cl
channel CLC-7, CYP51, and GST P1c.
Comparing Caco-2 cells (16 days) with Caco-2 cells (4
days), the following are the transporters, channels, and me-
Fig. 16. Expression of alkaline phosphatase and esterases in Caco-2 cells (4 days, black bar), Caco-2 cells (16 days, gray bar), and human
duodenum (blank bar). Expression levels were quantified by the intensity of hybridization signal. Putative carboxylesterase (accession number:
Y09616).
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tabolizing enzymes with at least a 3-fold expression differ-
ence:
I. Gene expression with more than a 3-fold increase (3- to
22-fold): (a) peptide transporters and related proteins: Na/H
exchanger KIAA. (b) Organic anion transporters and MRPs:
MCT U59185, MCT3, MRP3B, and MRP3. (c) Other trans-
porters: mitochondrial Fe transporter, Ca++ transporting
ATPase, liver fatty acid binding protein (FABP), ubiquitin
carrier E2-PEF, creatinine transporter, and sulfate trans-
porter. (d) Channels: water channel. (e) Metabolizing en-
zymes: carboxylesterase L07765, CYP reductase, CYP 27,
UGT C19, AcyT2, GST Ha2, ST 1A3, ST-P2, and cerebroside
ST. (f) Others: villin like protein, brush border myosin, and
mucin 2.
II. Gene expression with more than a 3-fold decrease (3-
to 12-fold): Glucose transporter (GLUT3), mdr1, MRP5,
Glutamate transporter D26443, GST-M4.
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